References
- 1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.10.1182/blood-2016-03-64354427069254
- 2. Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. Semin Hematol. 2015;52:200-206.10.1053/j.seminhematol.2015.03.00326111467
- 3. Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393-2398.10.1182/blood-2002-02-042012239147
- 4. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100:2387-2392.10.1182/blood-2002-01-019512239146
- 5. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62-70.10.1182/blood-2015-07-60454626660427
- 6. Pefani E, Panoskaltsis N, Mantalaris A, Georgiadis MC, Pistikopoulos EN. Chemotherapy drug scheduling for the induction treatment of patients with acute myeloid leukemia. IEEE Trans Biomed Eng. 2014;61:2049-2056.10.1109/TBME.2014.231322624686224
- 7. Kimby E, Nygren P, Glimelius B, et al. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol. 2001;40:231-252.10.1080/0284186015111632111441935
- 8. Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13:1-14.
- 9. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119:5133-5143.10.1182/blood-2011-06-36396022368270
- 10. Levis M. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncol. 2014;10:1571-1579.10.2217/fon.14.105608174025145428
- 11. Kayser S, Levis MJ, Schlenk RF. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Expert Rev Clin Pharmacol. 2017;10:1177-1189.10.1080/17512433.2017.138705128960095
- 12. How J, Sykes J, Minden MD, et al. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. Blood Cancer J. 2013;3:e116.10.1038/bcj.2013.14367445623708641
- 13. Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2016;09:693648.
- 14. Deol A, Sengsayadeth S, Ahn KW, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122:3005-3014.10.1002/cncr.30140503015127315441
- 15. Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011;117:2145-2155.10.1002/cncr.25670418442921523727